phenylalanine has been researched along with Glucose Intolerance in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 16 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akalestou, E; Alamshah, A; Amarsi, R; Amin, A; Bloom, SR; Cao, Y; Gonzalez-Abuin, N; Gray, GW; Johnson, R; Jomard, A; Kinsey-Jones, JS; Malik, Z; Moolla, A; Murphy, KG; Norton, M; Ramgulam, A; Saleh, K; Sargent, PR; Spreckley, E | 1 |
| Brancati, FL; Califf, RM; Chatterjee, R; Edelman, D; Svetkey, L; Thomas, L | 1 |
| Califf, RM; Chiang, FT; Giles, TD; Haffner, SM; Holman, RR; Mazzone, T; McMurray, JJ; Preiss, D; Rutten, GE; Standl, E; Sun, JL; Thomas, LE; Tognoni, G | 1 |
| Bethel, MA; Califf, RM; Chang, F; Disertori, M; Giles, TD; Haffner, SM; Holman, RR; Latini, R; Maggioni, AP; McMurray, JJ; Rutten, GE; Standl, E; Staszewsky, L; Sun, JL; Thomas, L; Tognoni, G | 1 |
| Bethel, MA; Califf, RM; Charbonnel, B; Diem, P; Haffner, SM; Holman, R; Horton, ES; Krum, H; Leiter, LA; Mareev, V; McMurray, JJ; Reyes, EM; Schaper, F; Shah, BR; Shen, L; Soska, V; Sun, JL; Thomas, L; Wojdyla, D | 1 |
| Califf, RM; Katz, M; Lopes, RD; McMurray, JJ; Sun, JL; Thomas, L | 1 |
| Bales, CW; Bethel, MA; Califf, RM; Davies, MJ; Haffner, SM; Holman, RR; Huffman, KM; Kraus, WE; McMurray, JJ; Preiss, D; Schulte, PJ; Thomas, L; Tuomilehto, J; Yates, T | 1 |
| Califf, RM; Davies, MJ; Gill, JM; Haffner, SM; Holman, RR; Kraus, WE; McMurray, JJ; Preiss, D; Thomas, LE; Wojdyla, DM; Yates, T | 1 |
| Arisawa, K; Ide, N; Kagawa, Y; Maeda, T; Ogura, K | 1 |
| Economopoulos, KP; Gharedaghi, MH; Gul, SS; Hamarneh, SR; Hamilton, AR; Hodin, RA; Hu, D; Huo, H; Hyoju, SK; Liu, W; Morrison, S; Munoz, AR; Phupitakphol, T; Zhang, W | 1 |
| Harumi Higuchi Dos Santos, M; Holman, RR; Lopes, RD; McMurray, JJ; Pieper, K; Sharma, A; Sun, JL | 1 |
| Bethel, M; Boolell, M; Califf, RM; Duggal, A; Haffner, SM; Holman, RR; McMurray, J | 1 |
| Bethel, MA; Califf, RM; Gerlock, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Krum, H; McMurray, JJ; Zuurman, L | 1 |
| Nathan, DM | 1 |
| Belenkov, Y; Bethel, MA; Boolell, M; Buckley, BM; Buse, JB; Califf, RM; Chacra, AR; Charbonnel, B; Chiang, FT; Chow, CC; Davies, MJ; Deedwania, P; Diem, P; Einhorn, D; Fonseca, V; Fulcher, GR; Gaciong, Z; Gaztambide, S; Giles, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Hua, TA; Ilkova, H; Jenssen, T; Kahn, SE; Krum, H; Laakso, M; Leiter, LA; Levitt, NS; Mareev, V; Martinez, F; Masson, C; Mazzone, T; McMurray, JJ; Meaney, E; Nesto, R; Pan, C; Prager, R; Raptis, SA; Rutten, GE; Sandstroem, H; Schaper, F; Scheen, A; Schmitz, O; Sinay, I; Soska, V; Stender, S; Tamás, G; Tognoni, G; Tuomilehto, J; Villamil, AS; Vozár, J | 2 |
| Allister, EM; Bhattacharjee, A; Wheeler, MB | 1 |
| Bentley, L; Browne, M; Cox, RD; Goldsworthy, M; Haynes, A; Hough, T; Hugill, A; Hunter, AJ; Mijat, V; Moir, L; Quarterman, J; Spurr, N; Toye, AA | 1 |
| Ohyama, Y; Tomono, S; Uchiyama, T | 1 |
| Hirose, T | 1 |
| Tsujii, S | 1 |
| Kawamori, R | 1 |
| Mori, Y | 1 |
| Arakawa, M; Hirose, T | 1 |
| Hanefeld, M; Julius, U; Nitzsche, S; Pietzsch, J | 1 |
| Iwamoto, Y; Omori, Y; Takizawa, T; Teno, S; Uto, Y | 1 |
6 review(s) available for phenylalanine and Glucose Intolerance
| Article | Year |
|---|---|
[Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].
Topics: Acarbose; Cyclohexanes; Fasting; Glucose Intolerance; Glycation End Products, Advanced; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Life Style; Myocardial Ischemia; Nateglinide; Phenylalanine; Pioglitazone; Postprandial Period; Protein Kinase C; Thiazolidinediones | 2005 |
[Effects of nateglinide in impaired glucose tolerance subjects].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Nateglinide; Obesity; Phenylalanine; Postprandial Period; Risk Factors | 2005 |
[NAVIGATOR trial (nateglinide)].
Topics: Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Endpoint Determination; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Life Style; Nateglinide; Phenylalanine; Primary Prevention; Randomized Controlled Trials as Topic; Risk | 2005 |
[Therapies for newly-onset diabetic patients].
Topics: Acarbose; Cyclohexanes; Diabetes Mellitus, Type 2; Diet Therapy; Enzyme Inhibitors; Exercise Therapy; Glucose; Glucose Intolerance; Glycogen; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Nateglinide; Phenylalanine; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
[Postprandial hypoglycemia].
Topics: Acarbose; Cyclohexanes; Diet, Carbohydrate-Restricted; Dietary Fiber; Dumping Syndrome; Enzyme Inhibitors; Gastrectomy; Glucose Intolerance; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Weight Loss | 2006 |
[Glinide(s), sulfonylurea(s)].
Topics: Arteriosclerosis; Cardiovascular Diseases; Cyclohexanes; Diabetic Angiopathies; Glucose Intolerance; Hyperglycemia; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Isoindoles; Nateglinide; Phenylalanine; Postprandial Period; Risk Factors; Sulfonylurea Compounds | 2006 |
8 trial(s) available for phenylalanine and Glucose Intolerance
| Article | Year |
|---|---|
Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
Topics: Antihypertensive Agents; Biomarkers; Cyclohexanes; Diabetes Mellitus; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Potassium; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Atrial Fibrillation; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2013 |
Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Confidence Intervals; Cyclohexanes; Female; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Prevalence; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan; Venous Thromboembolism | 2015 |
Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.
Topics: Body Weight; Cyclohexanes; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Motor Activity; Nateglinide; Phenylalanine; Prospective Studies; Valsartan | 2015 |
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cyclohexanes; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Research Design; Tetrazoles; Valine; Valsartan | 2008 |
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patient Selection; Phenylalanine; Prediabetic State; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Treatment Failure; Valine; Valsartan | 2010 |
Effect of valsartan on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
12 other study(ies) available for phenylalanine and Glucose Intolerance
| Article | Year |
|---|---|
l-phenylalanine modulates gut hormone release and glucose tolerance, and suppresses food intake through the calcium-sensing receptor in rodents.
Topics: Animals; Appetite Depressants; Appetite Regulation; Disease Models, Animal; Eating; Energy Metabolism; Gastrointestinal Hormones; Glucose Intolerance; Male; Mice; Mice, Inbred C57BL; Phenylalanine; Rats; Rats, Wistar; Receptors, Calcium-Sensing; Receptors, Gastrointestinal Hormone; Satiation | 2017 |
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Antihypertensive Agents; Comorbidity; Controlled Clinical Trials as Topic; Cyclohexanes; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Predictive Value of Tests; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2013 |
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Models, Statistical; Nateglinide; Phenylalanine; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial.
Topics: Accelerometry; Actigraphy; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cohort Studies; Cyclohexanes; Fasting; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Middle Aged; Motor Activity; Nateglinide; Phenylalanine; Prospective Studies; Regression Analysis; Risk Factors; Risk Reduction Behavior; Valsartan | 2015 |
Age-Dependent Onset of Insulin Resistance in Insulin-Resistant Mice.
Topics: Adipose Tissue; Age Factors; Animals; Blood Glucose; Cyclohexanes; Glucose; Glucose Intolerance; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice, Inbred Strains; Nateglinide; Obesity; Phenylalanine; Receptor, Insulin; RNA, Messenger | 2015 |
Inhibition of the gut enzyme intestinal alkaline phosphatase may explain how aspartame promotes glucose intolerance and obesity in mice.
Topics: Alkaline Phosphatase; Animals; Aspartame; Biomarkers; Biotransformation; Blood Glucose; Diet, High-Fat; Enzyme Inhibitors; Glucose Intolerance; Insulin Resistance; Intestinal Mucosa; Intestine, Small; Male; Metabolic Syndrome; Mice, Inbred C57BL; Non-Nutritive Sweeteners; Obesity; Phenylalanine; Tumor Necrosis Factor-alpha; Weight Gain | 2017 |
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asia; Australia; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Europe; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Latin America; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nateglinide; New Zealand; North America; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; South Africa; Stroke; Valsartan | 2017 |
Navigating the choices for diabetes prevention.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Tetrazoles; Valine; Valsartan | 2010 |
MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucose; Glucose Intolerance; Homeostasis; Hyperglycemia; Hyperinsulinism; Incretins; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Obese; Phenylalanine; Triazoles | 2012 |
A new mouse model of type 2 diabetes, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the glucokinase gene.
Topics: Adenine; Amino Acid Sequence; Amino Acid Substitution; Animals; Chromosome Mapping; Diabetes Mellitus, Type 2; Disease Models, Animal; Ethylnitrosourea; Glucokinase; Glucose; Glucose Intolerance; Heterozygote; Homozygote; Isoleucine; Male; Mice; Mice, Mutant Strains; Molecular Sequence Data; Mutagens; Mutation, Missense; Phenylalanine; Phosphorylation; Thymine | 2004 |
In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance.
Topics: Adult; Age Factors; Apolipoprotein A-I; Apolipoprotein A-II; Body Mass Index; Carbon Isotopes; Carrier Proteins; Cholesterol Ester Transfer Proteins; Female; Glucose Intolerance; Glycoproteins; Humans; Kinetics; Lipoprotein Lipase; Lipoproteins, HDL; Male; Middle Aged; Phenylalanine; Sex Factors; Statistics as Topic | 1998 |
Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
Topics: Adult; Aged; Blood Glucose; Cyclohexanes; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Time Factors | 2002 |